Northrop Grumman Developing PCR-Based Biodefense Dx System Under $9.6M BARDA Contract | GenomeWeb

This article, which was originally published on Nov. 5, has been updated from a previous version to include comments from Northrop Grumman and Agilent.

By Ben Butkus

Northrop Grumman said last week that it is developing a PCR-based diagnostic system to detect whether a person has been exposed to a biological threat under a $9.6 million contract from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."